<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36046159</PMID><DateRevised><Year>2022</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-0640</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in psychiatry</Title><ISOAbbreviation>Front Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Long-covid cognitive impairment: Cognitive assessment and apolipoprotein E (APOE) genotyping correlation in a Brazilian cohort.</ArticleTitle><Pagination><StartPage>947583</StartPage><MedlinePgn>947583</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">947583</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpsyt.2022.947583</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Few studies have objectively evaluated cognitive deficits after the acute phase of COVID-19 disease. Moreover, the role of apolipoprotein E (APOE) genotypes in cognitive decline in patients with COVID-19 has not been evaluated yet.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This cross-sectional study was conducted in confirmed cases of COVID-19 patients with neurological symptoms that persisted for more than 3 months from the onset. We determined APOE genotypes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The final sample consisted of 141 patients. The most frequent APOE genotype was E3/E3 (<i>N</i> = 95; 67.3%). In total, 93 patients (65.9%) had memory impairment symptoms as the main complaint, objectively confirmed through screening tests in 25 patients (17.7%). Patients with cognitive impairment had a lower frequency of anosmia than the normal and subjective cognitive decline (SCD) groups (<i>p</i> = 0.005). In addition, depression was recurrent in the cognitive impairment group and the SCD group (<i>p</i> = 0.046). Cognitive impairment was significantly more frequent in hospitalized patients and those with a lower education level. Cognitive status was not associated with APOE genotypes.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">Hospitalized patients had more severe infection with a greater possibility of systemic complications, greater inflammatory response, and prolonged hospitalization, which could impact cognitive performance. Cognitive impairment in patients with COVID-19 does not necessarily involve specific APOE polymorphisms. However, psychiatric disorders may also be responsible for cognitive complaints. Cognitive complaints are frequent in patients with COVID-19, even after the acute phase of the disease and in mild cases. Hospitalized participants and depressed patients may have a higher risk of cognitive impairment. APOE genotypes or haplotypes may not significantly play a role in COVID-19 cognitive impairment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Tavares-J&#xfa;nior, Oliveira, da Silva, Feitosa, Sousa, Cunha, Gaspar, Gomes, de Oliveira, Moreira-Nunes, Montenegro, Sobreira-Neto and Braga-Neto.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tavares-J&#xfa;nior</LastName><ForeName>Jos&#xe9; Wagner Leonel</ForeName><Initials>JWL</Initials><AffiliationInfo><Affiliation>Neurology Section, Department of Clinical Medicine, Faculty of Medicine, Federal University of Cear&#xe1; (UFC), Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Danilo Nunes</ForeName><Initials>DN</Initials><AffiliationInfo><Affiliation>Neurology Section, Department of Clinical Medicine, Faculty of Medicine, Federal University of Cear&#xe1; (UFC), Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Jean Breno Silveira</ForeName><Initials>JBS</Initials><AffiliationInfo><Affiliation>Drug Research and Development Center (NPDM), Pharmacogenetics Laboratory, Federal University of Cear&#xe1; (UFC), Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feitosa</LastName><ForeName>Werbety Lucas Queiroz</ForeName><Initials>WLQ</Initials><AffiliationInfo><Affiliation>Neurology Section, Department of Clinical Medicine, Faculty of Medicine, Federal University of Cear&#xe1; (UFC), Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sousa</LastName><ForeName>Artur Victor Menezes</ForeName><Initials>AVM</Initials><AffiliationInfo><Affiliation>Neurology Section, Department of Clinical Medicine, Faculty of Medicine, Federal University of Cear&#xe1; (UFC), Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunha</LastName><ForeName>Let&#xed;cia Chaves Vieira</ForeName><Initials>LCV</Initials><AffiliationInfo><Affiliation>Neurology Section, Department of Clinical Medicine, Faculty of Medicine, Federal University of Cear&#xe1; (UFC), Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaspar</LastName><ForeName>Safira de Brito</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Center of Health Sciences, State University of Cear&#xe1;, Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomes</LastName><ForeName>Carmem Meyve Pereira</ForeName><Initials>CMP</Initials><AffiliationInfo><Affiliation>Center of Health Sciences, State University of Cear&#xe1;, Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Oliveira</LastName><ForeName>La&#xed;s Lacerda Brasil</ForeName><Initials>LLB</Initials><AffiliationInfo><Affiliation>Drug Research and Development Center (NPDM), Pharmacogenetics Laboratory, Federal University of Cear&#xe1; (UFC), Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreira-Nunes</LastName><ForeName>Caroline Aquino</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Drug Research and Development Center (NPDM), Pharmacogenetics Laboratory, Federal University of Cear&#xe1; (UFC), Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montenegro</LastName><ForeName>Raquel Carvalho</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Drug Research and Development Center (NPDM), Pharmacogenetics Laboratory, Federal University of Cear&#xe1; (UFC), Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobreira-Neto</LastName><ForeName>Manoel Alves</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Neurology Section, Department of Clinical Medicine, Faculty of Medicine, Federal University of Cear&#xe1; (UFC), Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braga-Neto</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neurology Section, Department of Clinical Medicine, Faculty of Medicine, Federal University of Cear&#xe1; (UFC), Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Health Sciences, State University of Cear&#xe1;, Fortaleza, CE, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Psychiatry</MedlineTA><NlmUniqueID>101545006</NlmUniqueID><ISSNLinking>1664-0640</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">cognitive impairment</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">risk factor</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>1</Day><Hour>2</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36046159</ArticleId><ArticleId IdType="pmc">PMC9423011</ArticleId><ArticleId IdType="doi">10.3389/fpsyt.2022.947583</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guan WJ, Ni ZY, Hu Y, Liang W-H, Ou C-q, He J-x, et al. . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2019) 382:1708&#x2013;20. 10.1056/NEJMoa2002032</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. . Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. (2020) 87:18&#x2013;22. 10.1016/j.bbi.2020.03.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.03.031</ArticleId><ArticleId IdType="pmc">PMC7146689</ArticleId><ArticleId IdType="pubmed">32240762</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. . Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. (2020) 77:683&#x2013;90. 10.1001/jamaneurol.2020.1127</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Lu S, Chen J, Wei N, Wang D, Lyu H, et al. . The landscape of cognitive function in recovered COVID-19 patients. J Psychiatr Res. (2020) 129:98&#x2013;102. 10.1016/j.jpsychires.2020.06.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2020.06.022</ArticleId><ArticleId IdType="pmc">PMC7324344</ArticleId><ArticleId IdType="pubmed">32912598</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Brutto OH, Wu S, Mera RM, Costa AF, Recalde BY, Issa NP. Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: A longitudinal prospective study nested to a population cohort. Eur J Neurol. (2021) 28:1&#x2013;9. 10.1111/ene.14775</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14775</ArticleId><ArticleId IdType="pmc">PMC8014083</ArticleId><ArticleId IdType="pubmed">33576150</ArticleId></ArticleIdList></Reference><Reference><Citation>Delorme C, Paccoud O, Kas A, Hesters A, Bombois S, Shambrook P, et al. . COVID-19-related encephalopathy: a case series with brain FDG-positron-emission tomography/computed tomography findings. Eur J Neurol. (2020) 27:2651&#x2013;7. 10.1111/ene.14478</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14478</ArticleId><ArticleId IdType="pmc">PMC7461074</ArticleId><ArticleId IdType="pubmed">32881133</ArticleId></ArticleIdList></Reference><Reference><Citation>Cani I, Barone V, D'Angelo R, Pisani L, Allegri V, Spinardi L. Frontal encephalopathy related to hyperinflammation in COVID-19. J Neurol. (2021) 268:16&#x2013;19. 10.1007/s00415-020-10057-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10057-5</ArticleId><ArticleId IdType="pmc">PMC7353824</ArticleId><ArticleId IdType="pubmed">32654063</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo CL, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA, et al. . APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci. (2020) 75:2231&#x2013;2. 10.1093/gerona/glaa131</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glaa131</ArticleId><ArticleId IdType="pmc">PMC7314139</ArticleId><ArticleId IdType="pubmed">32451547</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S, et al. . Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. (1993) 342:697&#x2013;9. 10.1016/0140-6736(93)91705-Q</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(93)91705-Q</ArticleId><ArticleId IdType="pubmed">8103819</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Huang Q, Yu Z, Wu H, Zhong Z. The SNPs rs429358 and rs7412 of APOE gene are association with cerebral infarction but not SNPs rs2306283 and rs4149056 of SLCO1B1 gene in southern Chinese Hakka population. Lipids Health Dis. (2020) 19:202. 10.1186/s12944-020-01379-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-020-01379-4</ArticleId><ArticleId IdType="pmc">PMC7487494</ArticleId><ArticleId IdType="pubmed">32891149</ArticleId></ArticleIdList></Reference><Reference><Citation>Pendlebury ST, Rothwell PM, Oxford Vascular S. Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular study. Lancet Neurol. (2019) 18:248&#x2013;58. 10.1016/S1474-4422(18)30442-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30442-3</ArticleId><ArticleId IdType="pmc">PMC6390174</ArticleId><ArticleId IdType="pubmed">30784556</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovelis D, Segretti NO, Probst VS, Lareau SC, Brunetto AF, Pitta F. Validation of the modified pulmonary functional status and dyspnea questionnaire and the medical research council scale for use in Brazilian patients with chronic obstructive pulmonary disease. J Bras Pneumol. (2008) 34:1008&#x2013;18. 10.1590/S1806-37132008001200005</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1806-37132008001200005</ArticleId><ArticleId IdType="pubmed">19180335</ArticleId></ArticleIdList></Reference><Reference><Citation>Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry. (2006) 21:1078&#x2013;85. 10.1002/gps.1610</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.1610</ArticleId><ArticleId IdType="pubmed">16977673</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, Mchugh PR. Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res. (1975) 12:189&#x2013;98. 10.1016/0022-3956(75)90026-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. (1982) 140:566&#x2013;72. 10.1192/bjp.140.6.566</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.140.6.566</ArticleId><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. (1982) 37:323&#x2013;9. 10.1093/geronj/37.3.323</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronj/37.3.323</ArticleId><ArticleId IdType="pubmed">7069156</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. . Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. (1982&#x2013;1983) 17:37&#x2013;49. 10.1016/0022-3956(82)90033-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(82)90033-4</ArticleId><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck AT, Steer RA. Beck Depression Inventory Manual. Psychological Corporation, San Antonio.-References-Scientific Research Publishing, dispon&#xed;vel em:, acesso em: 2 set 2020 (1993).</Citation></Reference><Reference><Citation>Benites D, Gomes WB. The Prospective and Retrospective Memory Questionnaire's (PRMQ) translation, adaptation and preliminary validation. Psico-USF. (2007) 12:45&#x2013;54. 10.1590/S1413-82712007000100006</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1413-82712007000100006</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavares J&#xfa;nior, Jos&#xe9; Wagner Leonel. Avalia&#xe7;&#xe3;o da acur&#xe1;cia da escala de Addenbrooke como instrumento de rastreio cognitivo de pacientes idosos com baixa escolaridade/Jos&#xe9; Wagner Leonel Tavares J&#xfa;nior (2020).</Citation></Reference><Reference><Citation>C&#xe9;sar KG, Yassuda MS, Porto FHG, Brucki SMD, Nitrini R. Addenbrooke's cognitive examination-revised: normative and accuracy data for seniors with heterogeneous educational level in Brazil. Int Psychogeriatr. (2017) 29:1345&#x2013;53. 10.1017/S1041610217000734</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610217000734</ArticleId><ArticleId IdType="pubmed">28511735</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera E Jr, Caramelli P, Silveira AS, Nitrini R. Epidemiologic survey of dementia in a community-dwelling Brazilian population. Alzheimer Dis Assoc Disord. (2002) 16:103&#x2013;8. 10.1097/00002093-200204000-00007</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-200204000-00007</ArticleId><ArticleId IdType="pubmed">12040305</ArticleId></ArticleIdList></Reference><Reference><Citation>Brucki SMD, Nitrini R, Caramelli P, Bertolucci PHF, Okamoto IH. Sugest&#xf5;es para o uso do mini-exame do estado mental no Brasil. Arq neuropsiquiatr. (2003) 61:777&#x2013;81. 10.1590/S0004-282X2003000500014</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0004-282X2003000500014</ArticleId><ArticleId IdType="pubmed">14595482</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutra MC . Valida&#xe7;&#xe3;o do question&#xe1;rio de Pfeffer para popula&#xe7;&#xe3;o idosa brasileira. 72 f. Disserta&#xe7;&#xe3;o (Mestrado em Ci&#xea;ncias da Sa&#xfa;de)-Universidade Cat&#xf3;lica de Bras&#xed;lia, Bras&#xed;lia (2014).</Citation></Reference><Reference><Citation>Almeida OP, Almeida SA. Confiabilidade da vers&#xe3;o brasileira da Escala de Depress&#xe3;o em Geriatria (GDS) vers&#xe3;o reduzida. Arq Neuropsiquiatr. (1999) 57:421&#x2013;6. 10.1590/S0004-282X1999000300013</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0004-282X1999000300013</ArticleId><ArticleId IdType="pubmed">10450349</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Ch&#xe9;telat G, et al. . Subjective cognitive decline initiative (SCD-I) working group. a conceptual framework for research on subjective cognitive decline in preclinical alzheimer's disease. Alzheimers Dement. (2014) 10:844&#x2013;52. 10.1016/j.jalz.2014.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.01.001</ArticleId><ArticleId IdType="pmc">PMC4317324</ArticleId><ArticleId IdType="pubmed">24798886</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch W, Ehrenhaft A, Griesser K, Pfeufer A, M&#xfc;ller J, Sch&#xf6;mig A, et al. . TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E. Clin Chem Lab Med. (2002) 40:1123&#x2013;31. 10.1515/cclm.2002.197</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm.2002.197</ArticleId><ArticleId IdType="pubmed">12521230</ArticleId></ArticleIdList></Reference><Reference><Citation>Conover WJ, Conover WJ. Practical nonparametric statistics. 3rd ed. New York, NY: John Wiley &amp; Sons; (1999).</Citation></Reference><Reference><Citation>Akritas MG. Nonparametric statistical methods. 2nd ed. First Published August 1 (1999). 10.1177/096228029900800405</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096228029900800405</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp JA, Dressing A, Blazhenets G, Bormann T, Rau A, Schwabenland M, et al. . Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. (2021) 144:1263&#x2013;76. 10.1093/brain/awab009</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab009</ArticleId><ArticleId IdType="pmc">PMC8083602</ArticleId><ArticleId IdType="pubmed">33822001</ArticleId></ArticleIdList></Reference><Reference><Citation>Amalakanti S, Arepalli KVR, Jillella JP. Cognitive assessment in asymptomatic COVID-19 subjects. VirusDis. (2021) 32:146&#x2013;9. 10.1007/s13337-021-00663-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13337-021-00663-w</ArticleId><ArticleId IdType="pmc">PMC7883942</ArticleId><ArticleId IdType="pubmed">33614860</ArticleId></ArticleIdList></Reference><Reference><Citation>Honarmand K, Lalli RS, Priestap F, Chen JL, McIntyre CW, Owen AM, et al. . Natural History of Cognitive Impairment in Critical Illness Survivors. A systematic review. Am J Respir Crit Care Med. (2020) 202:193&#x2013;201. 10.1164/rccm.201904-0816CI</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201904-0816CI</ArticleId><ArticleId IdType="pmc">PMC7365360</ArticleId><ArticleId IdType="pubmed">32078780</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfoh ER, Chan KS, Dinglas VD, Girard TD, Jackson JC, Morris PE, et al. . Cognitive screening among acute respiratory failure survivors: a cross-sectional evaluation of the Mini-Mental State Examination. Crit Care. (2015) 19:220. 10.1186/s13054-015-0934-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-0934-5</ArticleId><ArticleId IdType="pmc">PMC4480909</ArticleId><ArticleId IdType="pubmed">25939482</ArticleId></ArticleIdList></Reference><Reference><Citation>Sartori AC, Vance DE, Slater LZ, Crowe M. The impact of inflammation on cognitive function in older adults: implications for health care practice and research. J Neurosci. Nurs. (2012) 44:206. 10.1097/JNN.0b013e3182527690</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JNN.0b013e3182527690</ArticleId><ArticleId IdType="pmc">PMC3390758</ArticleId><ArticleId IdType="pubmed">22743812</ArticleId></ArticleIdList></Reference><Reference><Citation>Negrini F, Ferrario I, Mazziotti D, Berchicci M, Bonazzi M, de Sire A, et al. . Neuropsychological features of severe hospitalized coronavirus disease (2019) patients at clinical stability and clues for postacute rehabilitation. Arch Phys Med Rehabil. (2021) 102:155&#x2013;8. 10.1016/j.apmr.2020.09.376</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apmr.2020.09.376</ArticleId><ArticleId IdType="pmc">PMC7521874</ArticleId><ArticleId IdType="pubmed">32991870</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavares-J&#xfa;nior JWL, de Souza ACC, Borges JWP, Oliveira DN, Siqueira-Neto JI, Sobreira-Neto MA, et al. . COVID-19 associated cognitive impairment: a systematic review. Cortex. (2022) 152:77&#x2013;97. 10.1016/j.cortex.2022.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cortex.2022.04.006</ArticleId><ArticleId IdType="pmc">PMC9014565</ArticleId><ArticleId IdType="pubmed">35537236</ArticleId></ArticleIdList></Reference><Reference><Citation>Crivelli L, Palmer K, Calandri I, Guekht A, Beghi E, Carroll W, et al. . Changes in cognitive functioning after COVID-19: a systematic review and meta-analysis. Alzheimers Dement. (2022) 18:1047&#x2013;66. 10.1002/alz.12644</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12644</ArticleId><ArticleId IdType="pmc">PMC9073922</ArticleId><ArticleId IdType="pubmed">35297561</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrekar-Colucci S, Landreth GE. Microglia and inflammation in Alzheimer's disease. CNS Neurol Disord Drug Targets. (2010) 9:156&#x2013;67. 10.2174/187152710791012071</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152710791012071</ArticleId><ArticleId IdType="pmc">PMC3653290</ArticleId><ArticleId IdType="pubmed">20205644</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibarreta L, G&#xf3;mez-Isla T, Portera-Sanchez A, Parrilla R, Ayuso-Parrilla MS. Apolipoprotein E genotype in Spanish patients of Alzheimer's or Parkinson's disease. J Neurol Sci. (1995) 134:146&#x2013;9. 10.1016/0022-510X(95)00238-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(95)00238-3</ArticleId><ArticleId IdType="pubmed">8747858</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux, et al. . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and alzheimer disease. A meta-analysis. APOE and alzheimer disease meta analysis consortium. JAMA. (1997) 278:1349&#x2013;56. 10.1001/jama.278.16.1349</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.278.16.1349</ArticleId><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhen J, Huang X, Halm-Lutterodt V, Dong S, Ma W, Xiao R, et al. . ApoE rs429358 and rs7412 Polymorphism and gender differences of serum lipid profile and cognition in aging Chinese population. Front Aging Neurosci. (2017) 9:248. 10.3389/fnagi.2017.00248</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00248</ArticleId><ArticleId IdType="pmc">PMC5539118</ArticleId><ArticleId IdType="pubmed">28824412</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez RD, Gomes I, Gomes C, Rocha R, Dur&#xe3;es L, Sousa P, et al. . APOE variants in an Iberian Alzheimer cohort detected through an optimized sanger sequencing protocol. Genes. (2021) 12:4. 10.3390/genes12010004</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes12010004</ArticleId><ArticleId IdType="pmc">PMC7822120</ArticleId><ArticleId IdType="pubmed">33375167</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendes-Lana A, Pena GG, Freitas SN, Lima AA, Nicolato RL, Nascimento-Neto RM, et al. . Apolipoprotein E polymorphism in Brazilian dyslipidemic individuals: Ouro Preto study. Braz J Med Biol Res. (2007) 40:49&#x2013;56. 10.1590/S0100-879X2007000100007</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0100-879X2007000100007</ArticleId><ArticleId IdType="pubmed">17224996</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham EL, Clark JR, Orban ZS. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 &#x201c;long haulers&#x201d;. Ann Clin Transl Neurol. (2021) 8:1073&#x2013;85. 10.1002/acn3.51350</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51350</ArticleId><ArticleId IdType="pmc">PMC8108421</ArticleId><ArticleId IdType="pubmed">33755344</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath AMD. Long-Haul COVID. Neurology. (2020) 95:559&#x2013;60. 10.1212/WNL.0000000000010640</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010640</ArticleId><ArticleId IdType="pubmed">32788251</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. (2021) 18:e1003773. 10.1371/journal.pmed.1003773</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. (2004) 256:183&#x2013;94. 10.1111/j.1365-2796.2004.01388.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2004.01388.x</ArticleId><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfsgruber S, Polcher A, Koppara A, Kleineidam L, Fr&#xf6;lich L, Peters O, et al. . Cerebrospinal fluid biomarkers and clinical progression in patients with subjective cognitive decline and mild cognitive impairment. J Alzheimers Dis. (2017) 58:939&#x2013;50. 10.3233/JAD-161252</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-161252</ArticleId><ArticleId IdType="pubmed">28527210</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckerstr&#xf6;m C, Olsson E, Bjerke M, Malmgren H, Edman A, Wallin A, et al. . A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia. J Alzheimers Dis. (2013) 36:421&#x2013;31. 10.3233/JAD-122440</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-122440</ArticleId><ArticleId IdType="pubmed">23635408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. (2006) 63:530&#x2013;8. 10.1001/archpsyc.63.5.530</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.63.5.530</ArticleId><ArticleId IdType="pmc">PMC3530614</ArticleId><ArticleId IdType="pubmed">16651510</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismael F, Bizario JCS, Battagin T, Zaramella B, Leal FE, Torales J, et al. . Post-infection depressive, anxiety and post-traumatic stress symptoms: a prospective cohort study in patients with mild COVID-19. Prog Neuropsychopharmacol Biol Psychiatry. (2021) 111:110341. 10.1016/j.pnpbp.2021.110341</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2021.110341</ArticleId><ArticleId IdType="pmc">PMC8086265</ArticleId><ArticleId IdType="pubmed">33940097</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. (2021) 398:1700&#x2013;12. 10.1016/S0140-6736(21)02143-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02143-7</ArticleId><ArticleId IdType="pmc">PMC8500697</ArticleId><ArticleId IdType="pubmed">34634250</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristillo V, Pilotto A, Cotti Piccinelli S, Zoppi N, Bonzi G, Gipponi S, et al. . Age and subtle cognitive impairment are associated with long-term olfactory dysfunction after COVID-19 infection. J Am Geriatr Soc. (2021) 69:2778&#x2013;80. 10.1111/jgs.17296</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.17296</ArticleId><ArticleId IdType="pmc">PMC8242714</ArticleId><ArticleId IdType="pubmed">34019707</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahiaoui-Doktor M, Luck T, Riedel-Heller SG, Loeffler M, Wirkner K, Engel C. Olfactory function is associated with cognitive performance: results from the population-based LIFE-Adult-Study. Alzheimers Res Ther. (2019) 11:43. 10.1186/s13195-019-0494-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0494-z</ArticleId><ArticleId IdType="pmc">PMC6511191</ArticleId><ArticleId IdType="pubmed">31077241</ArticleId></ArticleIdList></Reference><Reference><Citation>Martelletti P, Bentivegna E, Spuntarelli V, Luciani M. Long-COVID Headache. SN Compr Clin Med. (2021) 20:1&#x2013;3. 10.1080/14740338.2021.1907342</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2021.1907342</ArticleId><ArticleId IdType="pmc">PMC8136258</ArticleId><ArticleId IdType="pubmed">34036244</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaywant A, Vanderlind WM, Alexopoulos GS, Fridman CB, Perlis RH, Gunning FM. Frequency and profile of objective cognitive deficits in hospitalized patients recovering from COVID-19. Neuropsychopharmacology. (2021) 1&#x2013;6. 10.1101/2020.10.28.20221887</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.28.20221887</ArticleId><ArticleId IdType="pmc">PMC7884062</ArticleId><ArticleId IdType="pubmed">33589778</ArticleId></ArticleIdList></Reference><Reference><Citation>Puchner B, Sahanic S, Kirchmair R, Pizzini A, Sonnweber B, W&#xf6;ll E, et al. . Beneficial effects of multi-disciplinary rehabilitation in postacute COVID-19: an observational cohort study. Eur J Phys Rehabil Med. (2021) 57:189&#x2013;98. 10.23736/S1973-9087.21.06549-7</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S1973-9087.21.06549-7</ArticleId><ArticleId IdType="pubmed">33448756</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz N, Rodrigue KM. Differential aging of the brain: patterns, cognitive correlates and modifiers. Neurosci Biobehav Rev. (2006) 30:730&#x2013;48. 10.1016/j.neubiorev.2006.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2006.07.001</ArticleId><ArticleId IdType="pmc">PMC6601348</ArticleId><ArticleId IdType="pubmed">16919333</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. Statistical Power Analysis for the Behavioral Sciences. Routledge: (2013). 10.4324/9780203771587</Citation><ArticleIdList><ArticleId IdType="doi">10.4324/9780203771587</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral 1022 amyloid-beta accumulation earlier than positron emission tomography. Brain. (2016) 139:1226&#x2013;36. 10.1093/brain/aww015</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww015</ArticleId><ArticleId IdType="pmc">PMC4806222</ArticleId><ArticleId IdType="pubmed">26936941</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. . Discriminative accuracy of plasma Phospho-tau217 for alzheimer disease vs other neurodegenerative disorders. JAMA. (2020) 324:772&#x2013;81. 10.1001/jama.2020.12134</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>